Veradermics (NYSE:MANE) Sets New 52-Week High – Time to Buy?

Posted by Francis Steltz on Oct 22nd, 2026

Veradermics, Incorporated (NYSE:MANE – Get Free Report) hit a new 52-week high during trading on Thursday. The company traded as high as $139.12 and last traded at $137.0790, with a volume of 706,906 shares changing hands. The stock had previously closed at $127.11.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Citigroup restated a “buy” rating on shares of Veradermics in a report on Tuesday, September 15th. UBS Group set a $170.00 target price on Veradermics in a research report on Wednesday, July 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Veradermics in a report on Monday. Wall Street Zen raised shares of Veradermics from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Jefferies Financial Group lifted their price target on shares of Veradermics from $138.00 to $182.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $154.14.

Get Our Latest Report on Veradermics

Veradermics Trading Up 7.8%

The stock’s 50-day simple moving average is $110.08 and its two-hundred day simple moving average is $103.91.

Veradermics (NYSE:MANE – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.58). Equities analysts expect that Veradermics, Incorporated will post -2.74 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Reid Alexander Waldman sold 67,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $107.86, for a total transaction of $7,280,550.00. Following the completion of the sale, the chief executive officer owned 170,824 shares in the company, valued at $18,425,076.64. This represents a 28.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Childs sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $107.12, for a total value of $10,712,000.00. Following the completion of the sale, the director directly owned 194,117 shares in the company, valued at $20,793,813.04. This trade represents a 34.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 961,000 shares of company stock valued at $103,120,220.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Nvwm LLC lifted its holdings in shares of Veradermics by 105.4% during the third quarter. Nvwm LLC now owns 228 shares of the company’s stock worth $28,000 after buying an additional 117 shares during the last quarter. Private Capital Advisors Inc. boosted its position in shares of Veradermics by 158.4% in the third quarter. Private Capital Advisors Inc. now owns 6,291 shares of the company’s stock valued at $763,000 after acquiring an additional 3,856 shares during the period. Arizona State Retirement System acquired a new stake in shares of Veradermics in the second quarter worth $524,000. Seven Fleet Capital Management LP acquired a new stake in shares of Veradermics in the second quarter worth $9,835,000. Finally, Montanova Capital LLC acquired a new stake in shares of Veradermics in the second quarter worth $512,533,000.

About Veradermics

(Get Free Report)

Veradermics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for dermatologic conditions. The company’s research and development activities are directed toward treatments for diseases and disorders affecting the skin, hair and nails, with an emphasis on addressing areas where existing treatment options are limited.

Veradermics’ pipeline includes investigational topical therapies designed for conditions such as hair loss and other dermatological disorders.